CL2023003533A1 - Métodos para tratar el cáncer de mama - Google Patents

Métodos para tratar el cáncer de mama

Info

Publication number
CL2023003533A1
CL2023003533A1 CL2023003533A CL2023003533A CL2023003533A1 CL 2023003533 A1 CL2023003533 A1 CL 2023003533A1 CL 2023003533 A CL2023003533 A CL 2023003533A CL 2023003533 A CL2023003533 A CL 2023003533A CL 2023003533 A1 CL2023003533 A1 CL 2023003533A1
Authority
CL
Chile
Prior art keywords
breast cancer
methods
treating breast
subject
adjuvant
Prior art date
Application number
CL2023003533A
Other languages
English (en)
Spanish (es)
Inventor
Fielding Anitra
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2023003533A1 publication Critical patent/CL2023003533A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CL2023003533A 2021-06-02 2023-11-28 Métodos para tratar el cáncer de mama CL2023003533A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163195795P 2021-06-02 2021-06-02

Publications (1)

Publication Number Publication Date
CL2023003533A1 true CL2023003533A1 (es) 2024-06-28

Family

ID=82117716

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003533A CL2023003533A1 (es) 2021-06-02 2023-11-28 Métodos para tratar el cáncer de mama

Country Status (12)

Country Link
US (1) US20240269135A1 (cg-RX-API-DMAC10.html)
EP (1) EP4346828A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024520142A (cg-RX-API-DMAC10.html)
KR (1) KR20240016344A (cg-RX-API-DMAC10.html)
CN (1) CN118139624A (cg-RX-API-DMAC10.html)
AU (1) AU2022286616A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023025003A2 (cg-RX-API-DMAC10.html)
CA (1) CA3220751A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003533A1 (cg-RX-API-DMAC10.html)
IL (1) IL308684A (cg-RX-API-DMAC10.html)
MX (1) MX2023014420A (cg-RX-API-DMAC10.html)
WO (1) WO2022253800A1 (cg-RX-API-DMAC10.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu

Also Published As

Publication number Publication date
IL308684A (en) 2024-01-01
WO2022253800A1 (en) 2022-12-08
KR20240016344A (ko) 2024-02-06
CA3220751A1 (en) 2022-12-08
BR112023025003A2 (pt) 2024-02-20
CN118139624A (zh) 2024-06-04
US20240269135A1 (en) 2024-08-15
MX2023014420A (es) 2024-04-23
AU2022286616A1 (en) 2024-01-18
JP2024520142A (ja) 2024-05-21
EP4346828A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
CL2024001473A1 (es) Conjugados de fármacos y anticuerpos anti-ccr7
JOP20190254A1 (ar) مركبات مضادة للأورام
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CU20210098A7 (es) Derivados de quinazolin-4-one útiles para el tratamiento de enfermedades y trastornos asociados con braf
UY38360A (es) Métodos de tratamiento del cáncer
MX2021004881A (es) Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
PA8637101A1 (es) Terapia para el cancer resistente al platino
MX2019014021A (es) Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo.
NI201000083A (es) Tratamiento de cáncer de mama con un compuesto de 4 - iodo - 3 - nitrobenzamida en combinación con agentes anti-tumorales.
ECSP17013466A (es) Inhibidores de desmetilasa-1 específica a lisina
MX2022007974A (es) Metodos de tratamiento del cancer con anticuerpos anti-cd70 no fucosilados.
MX2023008327A (es) Anticuerpos inmunomoduladores de anticuerpo-farmaco.
CO2024009571A2 (es) Inhibidores de parp1
ECSP17020172A (es) Inhibidores de histona desmetilasa
CO2023009803A2 (es) Quinolinas y azaquinolinas como inhibidores de cd38
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
MX2019009304A (es) Tratamiento para el cancer.
PE20180454A1 (es) Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2
PH12017501879A1 (en) Methods for treating cancer
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
BR112022001045A2 (pt) Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit
MX2021009182A (es) Antiandrogenos para el tratamiento de cancer de prostata metastasico sensible a la castracion.
MX2019009356A (es) Sulfinilpiridinas y su uso en el tratamiento del cancer.
CR20230048A (es) Procesos para elaborar compuestos serd tricíclicos que tienen un resto sustituido de fenilo o piridinilo
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres